<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Efstathiou, E.</style></author><author><style face="normal" font="default" size="100%">Gika, D.</style></author><author><style face="normal" font="default" size="100%">Bozas, G.</style></author><author><style face="normal" font="default" size="100%">Zorzou, P.</style></author><author><style face="normal" font="default" size="100%">Sarris, K.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Gynecologic Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cervical cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Non-squamous</style></keyword><keyword><style  face="normal" font="default" size="100%">Platinum</style></keyword><keyword><style  face="normal" font="default" size="100%">Recurrent</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-27144547596&amp;doi=10.1016%2fj.ygyno.2005.06.024&amp;partnerID=40&amp;md5=bd53b96c9ece45b1bf2dcd7fc8a4b370</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">99</style></volume><pages><style face="normal" font="default" size="100%">376 - 382</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background. Data about the outcome and prognostic factors in the group of patients with non-squamous cell advanced or recurrent carcinomas of the uterine cervix are limited. We compared the outcome of patients with non-squamous with that of squamous cell carcinomas after platinum-based combination chemotherapy as first line therapy for stage IV or recurrent cervical carcinoma. Patients and methods. A total of 200 patients with stage IV or recurrent carcinomas of the cervix received platinum-based combination chemotherapy and were included in our analysis. Results. There were 58 patients with non-squamous and 142 patients with squamous cell carcinomas. Response to chemotherapy was 53.5% in non-squamous vs. 43.5% in squamous carcinomas. Histology was not an independent predictor of tumor response (P = 0.797). Response rates were lower in patients with relapse only in a previously irradiated area in both squamous (26.9% vs. 53.5%, P = 0.005) and non-squamous carcinomas (47.1% vs. 65%, P = 0.270). Weight loss was the only significant predictor of survival in non-squamous histology patients (P &lt;0.0001). There was no significant difference in median survival between squamous (11.57 months [95% CI 9.35-13.79]) and non-squamous carcinomas (19.05 months [95% CI 13.63-24.47]) (P = 0.064). After adjustment for independent prognostic factors (ECOG performance status and weight loss), differences in survival remained not significant. Conclusion. Our study showed a similar outcome for both squamous and non-squamous stage IV or recurrent cervical carcinomas treated with platinum-based combination chemotherapy. © 2005 Elsevier Inc. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><notes><style face="normal" font="default" size="100%">Cited By :24Export Date: 21 February 2017</style></notes></record></records></xml>